Cervical Cancer Diagnostics and Therapeutics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Cervical Cancer Diagnostics and Therapeutics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The Cervical Cancer Diagnostics and Therapeutics Market is expected to grow at the registered CAGR of 5.2% during the forecast period, 2022-2027.

The COVID-19 pandemic had a serious impact on cervical cancer diagnosis and treatment. According to the study titled "COVID-19 Pandemic Effects on Cervical Cancer Diagnosis and Management: A Population-Based Study in Romania" published in the Diagnostics Journal in April 2022, During the first lockdown in April 2020, the number of tests dropped by 75.5 %, after which the number of cases dropped by up to 36.1 % 2021. During the first 24 months of the pandemic, the total volume of tests lost was 49.9%. The percentage of late-stage cervical cancers (stages III-IV) increased by 17%, while the number of newly diagnosed cancers in our outpatient clinic decreased by 45% from the baseline. Access to cancer care was harmed, with 9.2% more patients waiting longer for test results, taking longer to seek cancer treatment after diagnosis, and missing significantly more appointments. Thus, the COVID-19 hampers the growth of the market.

The factors propelling the growth of the cervical cancer diagnostics and therapeutics market are favorable government initiatives toward cervical cancer prevention, growing prevalence of cervical cancer, increasing awareness regarding early diagnosis, and strong R&D from key players of cervical cancer diagnosis and drugs. For instance, in November 2020, Through the adoption of a resolution by 194 countries at the World Health Assembly, WHO launched a global initiative to accelerate the elimination of cervical cancer and set a historic milestone by pledging, for the first time, to eliminate a malignant disease by pursuing three important steps: vaccination, screening, and treatment. Additionally, in May 2022, The National Health Mission (NHM) and the Clinton Health Access Initiative launched a training programme for gynaecologists and nurses in Utter Pradesh (India) with the goal of detecting cervical cancer cases at an early stage. Such initiatives by the government supports the early diagnosis and treatment of the cervical cancer, thereby boost the market growth.

The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of cervical cancer among women worldwide. According to the World Health Organization Updates in February 2022, Cervical cancer is the fourth most common cancer in women worldwide, with 604 000 new cases and 342 000 deaths by 2020. In 2020, low- and middle-income countries will account for nearly 90% of new cases and deaths worldwide. With the rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer, the market is expected to grow.

Increasing awareness among the general population regarding the care, prevention, and treatment of cervical cancer, rise in certain behaviors, such as sex with multiple partners and smoking, certain genetic factors, and weak immune system are all linked to the growth of the cervical cancer diagnostics and therapeutics market. Awareness programs have helped in the growth of the market. For instance, In July 2020, Medicaid, the popular government insurance program, covers the screening for cervical cancers. Medicare, another widely used insurance, covers Pap test, pelvic exam, and clinical breast exam for cervical cancer screening every two years. These programs were found to be responsible for the growth of the overall market.

However, economic constraints in many countries to adopt regular testing procedures and high cost of cancer therapy restraint the market growth.

The Papanicolaou test is a cervical screening method that can detect precancerous and cancerous processes in the cervix and colon. Abnormal findings are frequently followed by more sensitive diagnostic procedures and, if necessary, interventions aimed at preventing cervical cancer progression. An HPV test is recommended for women over 30 to detect the virus. The screening aids in detecting precancerous lesions caused by HPV, which can then be removed to prevent the development of invasive cancers.

The major factor driving the segment's growth includes the rising burden of cervical cancer across the world. The disease is more commonly found in females. According to the Cervical Cancer Statistics 2020, Invasive cervical cancer was diagnosed in approximately 14,100 women in United States. In 2020, an estimated 604,127 women were diagnosed with cervical cancer worldwide. Additionally, according to the Report of HPV Centre Japan in October 2021, In Japan, approximately 12,785 new cervical cancer cases are diagnosed each year (estimations for 2020). Cervical cancer is the tenth leading cause of cancer in women in Japan. Cervical cancer is the second most common cancer in Japanese women aged 15 to 44. Therefore, the incidence of cervical cancer is found to increase every year. In most cases, cervical cancer can be prevented through early detection and treatment of abnormal cell changes in the cervix years before cervical cancer develops. Therefore, with the increasing adoption of early diagnosis, the market is expected to grow positively during the forecast period.

Increasing product launches in the country boost the market. For instance, in May 2021 BD (Becton, Dickinson and Company) Introduced the industry's one of the first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC. Thus, due to the increasing demand for Pap, HPV, and other tests for cancer screening, the market is expected to grow. Similarly, in April 2020, Roche received United States Food and Drug Administration (FDA) approval for the cobas HPV test for use on the fully automated, high-throughput cobas 6800/8800 Systems. The cobas HPV test identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples.

Thus, all aforementioned factors anticipated to drive the segment growth over the forecast period.

North America is one of the largest markets for cervical cancer diagnostics and therapeutics. The large market share is attributed to the high awareness about disease prevention among women in the region, as well as to the many initiatives launched to prevent cervical cancer, which has increased the reach of insurance coverage for cervical screening tests, especially for low-income women.

Cervical cancer is found to be one of the most common causes of death among women in United States. According to the American Cancer Society, in 2020, there were around 13,800 new cases of invasive cervical cancer that were being diagnosed, and about 4,290 women died from cervical cancer. The death rate due to cervical cancer has dropped over the last 40 years, by up to more than 50%, with the increased use of testing.

Additionally, favorable government policies in United States are expected to drive the overall market during the forecast period. As per the Center for Diseases Control and Prevention Updates in February 2022, in United States, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for breast and cervical cancer screening has helped in driving the overall market growth. Additionally, The month of January has been designated as Cervical Health Awareness Month by United States Congress. National Cervical Cancer Coalition (NCCC) and its many local chapters across the country raise awareness about cervical cancer, HPV disease, and the importance of early detection during the month of January. While NCCC chapters host events throughout the year, Cervical Health Awareness Month is observed in January, and chapters work to raise awareness in their communities.

However, growing product launches by the key market players supports the market growth. For instance, in September 2021, Food and Drug Administration granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Thus, in view of the above-mentioned facts, the studied market is expected to propel in United States over the forecast period

The cervical cancer diagnostics and therapeutics market is fragmented, competitive, and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Companies are currently focusing on developing advanced techniques for diagnosis, such as liquid-based cytology. Some of the companies currently dominating the market are Abbott Laboratories, Bristol-Meyrs Squibb Company, GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Qiagen NV, Advaxis Inc., Becton, Dickinson and Company, and F. Hoffmann-La Roche Ltd.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support